Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 4/20 | 0.33 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.33 |
| ▸ | RXRA | P19793 | 4/20 | 0.32 |
| ▸ | RXRB | P28702 | 3/20 | 0.32 |
| ▸ | RXRG | P48443 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | BLVRB | P30043 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23446772 | 0.84 | RXRA (0.34) | CYP26A1RXRARXRBRXRGRARA | |
| SCHEMBL23445131 | 0.84 | RXRA (0.32) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL23445069 | 0.83 | RXRA (0.31) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL23445736 | 0.82 | CYP26A1 (0.35) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL23446086 | 0.82 | KIF11 (0.37) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL23446046 | 0.81 | RXRA (0.32) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL23445608 | 0.81 | CYP26A1 (0.33) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL22948156 | 0.81 | RXRA (0.40) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL23445079 | 0.80 | RXRA (0.30) | RXRARXRBRXRG | |
| SCHEMBL24085024 | 0.79 | CYP26A1 (0.34) | CYP26A1CYP26B1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780856-B2 | Compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2023-10-10 | — | — | US | disclosed |
| US-11780856-B2 | Compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2023-10-10 | — | — | US | disclosed |
| WO-2021107681-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780856-B2 | Compound and organic light-emitting device comprising same | CRY1, CRY2, LEF1 | CYP26A1 103/4885CYP26B1 109/4885RXRA 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.